Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented updates from its Phase II SUMMIT Basket Trial of neratinib in EGFR exon 18-mutant NSCLC at EORTC/NCI/AACR 2022 Symp.

Click to view original post